It has a market cap of $430 billion, but Pot believes it could double as it develops more weight-loss products
It can speed up muscle growth, fat loss, and recovery, but it bypasses the bodys natural endocrine regulation, which may increase the risk of side effects like insulin resistance, fluid retention, and joint pain
A safety update on sodium glucose co-transporter 2 inhibitors
About the Phase 2b Study 1 The phase 2b study was a 26-week, randomized, placebo-controlled study comparing the effects of four doses (1 mg, 5 mg, 10 mg, 15 mg) of Lilly's novel long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist to dulaglutide 1.5 mg and placebo in people with type 2 diabetes
Howard AD, Feighner SD, Cully DF, et al